.svg)
Biotech Investment and Financing
Venture CapitalPrivate EquityCorporate Venture CapitalPublic-Market Financing
BioEquity Europe 2027
Edition27 A European biopharma investment and partnering conference connecting biotech companies, venture investors and pharma business-development teams.
BioEquity Europe is an investment, financing and partnering conference for the European and global biopharmaceutical innovation ecosystem, bringing together biotech founders, investment institutions, pharma business development and licensing teams and industry decision-makers for project pitches, partnering discussions and deal-making, now in its 27th edition.
The conference is held in Copenhagen, Denmark, drawing on the local Medicon Valley life science cluster. Known in Europe for an efficient clinical research environment and dense research infrastructure, the region hosts nearly 600 life science companies, 9 research universities and 32 hospitals, providing an industry base for clinical translation and international collaboration of biopharmaceutical projects.
Session topics include how European biotech companies can shorten the path from discovery to clinic and improve asset de-risking efficiency to attract investors and pharma; how European companies can differentiate amid intensifying global competition, rising momentum in Asia and an uncertain regulatory environment; and current opportunities, talent reserves, operational capabilities and cross-border collaboration in Copenhagen and the Nordic region.
The conference includes a company presentation track selecting more than 100 emerging biotech companies to pitch; one-to-one partnering meetings with investors and pharma business development teams; and a European biotech trends report from partner McKinsey, alongside exchange and panel discussions for venture investors, company leaders and licensing teams.
Area
Exhibitors
Visitors
Bio€quity Europe is the premier annual gathering of the corporate and investment communities for the global life sciences industry. Co-organized by BioCentury and EBD Group, it brings together biotech CEOs, venture capitalists, private equity investors, pharma BD&L leaders and financial dealmakers to network, partner and debate the critical issues shaping the biotech industry. Now in its 27th edition, Bio€quity Europe is the longest-running and most senior-level biotech investor conference in Europe. No biotech event attracts a higher concentration of investors. Although anchored in Europe, Bio€quity Europe is a truly global event, with investors and dealmakers attending from Europe, the United States and Asia. Every European biotech that aspires to globalize — whether by attracting U.S. investors for a NASDAQ IPO, licensing assets to global pharma, or commercializing in the U.S., the world's largest pharma market — will find the right people in the room at Bio€quity Europe. Past Faculty and delegates have included leaders from Sofinnova Partners, Forbion, Jeito Capital, Gilde Healthcare, EQT Life Sciences, Kurma Partners, Andera Partners, RA Capital, OrbiMed, Novo Holdings, LSP, BioMedPartners, MSD, Bayer, Novartis, Roche, Sanofi, Johnson & Johnson, MoonLake Immunotherapeutics, Candel Therapeutics and many more.
The 27th Bio€quity Europe takes place May 10–12, 2027, at the Tivoli Hotel & Congress Center (Arni Magnussons Gade 2, 1577 Copenhagen, Denmark). Digital partnering days to follow.
Bio€quity Europe returns to Copenhagen for the first time since 2016, and the city's life science ecosystem has grown considerably in the decade since. Copenhagen sits at the heart of Medicon Valley, one of Europe's most dynamic and fastest-growing life science clusters. The cross-border region spanning eastern Denmark and southern Sweden is home to nearly 600 life science companies, 9 research universities, and 32 hospitals — an unusually high density of talent, capital, and infrastructure concentrated in a relatively compact geography. For biotech CEOs, board members and investors attending Bio€quity, Copenhagen offers direct access to an ecosystem that punches well above its weight. Denmark is home to global pharma innovators like Novo Nordisk, Lundbeck, LEO Pharma, and Bavarian Nordic, as well as leading biotechs such as Genmab and Zealand Pharma — companies that have demonstrated how world-class science can be translated into venture-backed, globally competitive businesses. Among the success stories, Genmab has grown into the most valuable biotech in Europe, a model for what the continent's ecosystem can produce. Copenhagen also offers a distinctive edge on clinical development and manufacturing — directly aligned with Bio€quity's focus on accelerating the path from discovery to clinic. Medicon Valley ranks second in Europe for density of research facilities and leads in the number of CDMO sites, while its Trial Nation public-private partnership supported 455 commercial trials in 2024 alone. Each year Bio€quity Europe rotates to a new European city to spotlight regional innovation ecosystems, with recent editions held in Prague, Bruges, San Sebastián, Dublin and Milan.
Bio€quity Europe is co-organized by BioCentury and Informa (Formerly EBD Group, an Informa Connect business). BioCentury has provided essential business intelligence to biopharma executives and investors for 30+ years, and Informa operates the partneringONE® platform used for one-to-one meeting scheduling at the event. McKinsey & Company serves as Insights Partner.
Yes. Bio€quity Europe sells out every year. Attendance is capped at 1,200 delegates to ensure a high-quality experience for networking, partnering and debate among peers. We strongly encourage early registration to secure your place.
Bio€quity Europe is a senior-level event designed for decision-makers across the biopharma investment and corporate ecosystem: Biotech C-suite: CEOs, CFOs and CBOs of growth-stage biotechnology companies. Investors: Venture capitalists, private equity investors and corporate venture arms from Europe, the U.S. and Asia. Pharma BD&L leaders: Business development and licensing executives from global pharmaceutical companies. Financial dealmakers: Investment bankers and advisors active in life sciences. No biotech event attracts a higher concentration of investors. If you are a European biotech looking to attract global capital, or a U.S. or Asia investor looking to source innovation from Europe, Bio€quity Europe is where the deals get started.
Bio€quity Europe attracts 1,000+ executives and investors from over 30 countries. Although anchored in Europe, the event is truly global, with leading biotech investors attending from the U.S. and Asia alongside Europe's most active VCs and pharma BD&L executives. Delegates and Faculty at recent Bio€quity Europe events have included leaders from Sofinnova Partners, Forbion, Jeito Capital, Gilde Healthcare, EQT Life Sciences, Kurma Partners, Andera Partners, RA Capital, OrbiMed, Novo Holdings, LSP, BioMedPartners, MSD, Bayer, Novartis, Roche, Sanofi, Johnson & Johnson, MoonLake Immunotherapeutics, Candel Therapeutics, Idorsia and many more.
Last year's program explored how European biotech can accelerate to compete and lead in today's world. Expect strategic panels and debates on: How Europe can shorten the path from discovery to the clinic — practical strategies to accelerate development timelines, rapidly reach first-in-human data and de-risk assets to attract investors and pharma. Where Europe can win as global competition intensifies — a clear-eyed view of how European biotechs can differentiate themselves on the global stage amid rising momentum from Asia and policy uncertainty in the U.S. Why Central and Eastern Europe matter now — insights into emerging opportunities, talent pools, cost and operational efficiencies, and partnerships from life sciences leaders in the region. You will also receive an exclusive conference report from Insights Partner McKinsey & Company on European biotech trends, and hear directly from top biotech VCs including partners from Sofinnova, Forbion, Jeito Capital, EQT, Gilde and many more who take the stage as Faculty.
Register online at the Bio€quity Europe 2027 registration page. You will be asked to select your registration category (General Registration or Service Provider Registration) during the process.
Bio€quity Europe offers two registration categories: All-Access General Registration: For biotech, pharma, diagnostics, medical device companies and investors. All-Access Service Provider Registration: For CROs, CMOs, economic development organizations, law firms, consultants and other service providers.
BioEquity Europe 2027
Edition27 A European biopharma investment and partnering conference connecting biotech companies, venture investors and pharma business-development teams.
BioEquity Europe is an investment, financing and partnering conference for the European and global biopharmaceutical innovation ecosystem, bringing together biotech founders, investment institutions, pharma business development and licensing teams and industry decision-makers for project pitches, partnering discussions and deal-making, now in its 27th edition.
The conference is held in Copenhagen, Denmark, drawing on the local Medicon Valley life science cluster. Known in Europe for an efficient clinical research environment and dense research infrastructure, the region hosts nearly 600 life science companies, 9 research universities and 32 hospitals, providing an industry base for clinical translation and international collaboration of biopharmaceutical projects.
Session topics include how European biotech companies can shorten the path from discovery to clinic and improve asset de-risking efficiency to attract investors and pharma; how European companies can differentiate amid intensifying global competition, rising momentum in Asia and an uncertain regulatory environment; and current opportunities, talent reserves, operational capabilities and cross-border collaboration in Copenhagen and the Nordic region.
The conference includes a company presentation track selecting more than 100 emerging biotech companies to pitch; one-to-one partnering meetings with investors and pharma business development teams; and a European biotech trends report from partner McKinsey, alongside exchange and panel discussions for venture investors, company leaders and licensing teams.
Area
Exhibitors
Visitors
Bio€quity Europe is the premier annual gathering of the corporate and investment communities for the global life sciences industry. Co-organized by BioCentury and EBD Group, it brings together biotech CEOs, venture capitalists, private equity investors, pharma BD&L leaders and financial dealmakers to network, partner and debate the critical issues shaping the biotech industry. Now in its 27th edition, Bio€quity Europe is the longest-running and most senior-level biotech investor conference in Europe. No biotech event attracts a higher concentration of investors. Although anchored in Europe, Bio€quity Europe is a truly global event, with investors and dealmakers attending from Europe, the United States and Asia. Every European biotech that aspires to globalize — whether by attracting U.S. investors for a NASDAQ IPO, licensing assets to global pharma, or commercializing in the U.S., the world's largest pharma market — will find the right people in the room at Bio€quity Europe. Past Faculty and delegates have included leaders from Sofinnova Partners, Forbion, Jeito Capital, Gilde Healthcare, EQT Life Sciences, Kurma Partners, Andera Partners, RA Capital, OrbiMed, Novo Holdings, LSP, BioMedPartners, MSD, Bayer, Novartis, Roche, Sanofi, Johnson & Johnson, MoonLake Immunotherapeutics, Candel Therapeutics and many more.
The 27th Bio€quity Europe takes place May 10–12, 2027, at the Tivoli Hotel & Congress Center (Arni Magnussons Gade 2, 1577 Copenhagen, Denmark). Digital partnering days to follow.
Bio€quity Europe returns to Copenhagen for the first time since 2016, and the city's life science ecosystem has grown considerably in the decade since. Copenhagen sits at the heart of Medicon Valley, one of Europe's most dynamic and fastest-growing life science clusters. The cross-border region spanning eastern Denmark and southern Sweden is home to nearly 600 life science companies, 9 research universities, and 32 hospitals — an unusually high density of talent, capital, and infrastructure concentrated in a relatively compact geography. For biotech CEOs, board members and investors attending Bio€quity, Copenhagen offers direct access to an ecosystem that punches well above its weight. Denmark is home to global pharma innovators like Novo Nordisk, Lundbeck, LEO Pharma, and Bavarian Nordic, as well as leading biotechs such as Genmab and Zealand Pharma — companies that have demonstrated how world-class science can be translated into venture-backed, globally competitive businesses. Among the success stories, Genmab has grown into the most valuable biotech in Europe, a model for what the continent's ecosystem can produce. Copenhagen also offers a distinctive edge on clinical development and manufacturing — directly aligned with Bio€quity's focus on accelerating the path from discovery to clinic. Medicon Valley ranks second in Europe for density of research facilities and leads in the number of CDMO sites, while its Trial Nation public-private partnership supported 455 commercial trials in 2024 alone. Each year Bio€quity Europe rotates to a new European city to spotlight regional innovation ecosystems, with recent editions held in Prague, Bruges, San Sebastián, Dublin and Milan.
Bio€quity Europe is co-organized by BioCentury and Informa (Formerly EBD Group, an Informa Connect business). BioCentury has provided essential business intelligence to biopharma executives and investors for 30+ years, and Informa operates the partneringONE® platform used for one-to-one meeting scheduling at the event. McKinsey & Company serves as Insights Partner.
Yes. Bio€quity Europe sells out every year. Attendance is capped at 1,200 delegates to ensure a high-quality experience for networking, partnering and debate among peers. We strongly encourage early registration to secure your place.
Bio€quity Europe is a senior-level event designed for decision-makers across the biopharma investment and corporate ecosystem: Biotech C-suite: CEOs, CFOs and CBOs of growth-stage biotechnology companies. Investors: Venture capitalists, private equity investors and corporate venture arms from Europe, the U.S. and Asia. Pharma BD&L leaders: Business development and licensing executives from global pharmaceutical companies. Financial dealmakers: Investment bankers and advisors active in life sciences. No biotech event attracts a higher concentration of investors. If you are a European biotech looking to attract global capital, or a U.S. or Asia investor looking to source innovation from Europe, Bio€quity Europe is where the deals get started.
Bio€quity Europe attracts 1,000+ executives and investors from over 30 countries. Although anchored in Europe, the event is truly global, with leading biotech investors attending from the U.S. and Asia alongside Europe's most active VCs and pharma BD&L executives. Delegates and Faculty at recent Bio€quity Europe events have included leaders from Sofinnova Partners, Forbion, Jeito Capital, Gilde Healthcare, EQT Life Sciences, Kurma Partners, Andera Partners, RA Capital, OrbiMed, Novo Holdings, LSP, BioMedPartners, MSD, Bayer, Novartis, Roche, Sanofi, Johnson & Johnson, MoonLake Immunotherapeutics, Candel Therapeutics, Idorsia and many more.
Last year's program explored how European biotech can accelerate to compete and lead in today's world. Expect strategic panels and debates on: How Europe can shorten the path from discovery to the clinic — practical strategies to accelerate development timelines, rapidly reach first-in-human data and de-risk assets to attract investors and pharma. Where Europe can win as global competition intensifies — a clear-eyed view of how European biotechs can differentiate themselves on the global stage amid rising momentum from Asia and policy uncertainty in the U.S. Why Central and Eastern Europe matter now — insights into emerging opportunities, talent pools, cost and operational efficiencies, and partnerships from life sciences leaders in the region. You will also receive an exclusive conference report from Insights Partner McKinsey & Company on European biotech trends, and hear directly from top biotech VCs including partners from Sofinnova, Forbion, Jeito Capital, EQT, Gilde and many more who take the stage as Faculty.
Register online at the Bio€quity Europe 2027 registration page. You will be asked to select your registration category (General Registration or Service Provider Registration) during the process.
Bio€quity Europe offers two registration categories: All-Access General Registration: For biotech, pharma, diagnostics, medical device companies and investors. All-Access Service Provider Registration: For CROs, CMOs, economic development organizations, law firms, consultants and other service providers.
Coming Soon
19940848151
support@expofinder.com
